NCT06157099 - Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA, IIB, or IIIA Melanoma | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

September 1, 2024

Primary Completion Date

March 1, 2028

Study Completion Date

September 1, 2029

Conditions

Pathologic Stage IIIA Cutaneous Melanoma AJCC v8Pathologic Stage IIA Cutaneous Melanoma AJCC v8Pathologic Stage IIB Cutaneous Melanoma AJCC v8

Interventions

DRUG

Atorvastatin

Given PO

DRUG

Placebo Administration

Given orally (PO)

PROCEDURE

Computed Tomography

Undergo CT

PROCEDURE

Magnetic Resonance Imaging

Undergo MRI

OTHER

Electronic Health Record Review

Ancillary studies

Trial Locations (1)

RECRUITING

OHSU Knight Cancer Institute, Portland